Novartis AG ADR (NVS)vsOnconetix Inc (ONCO)
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
ONCO
Onconetix Inc
$1.09
-4.39%
HEALTHCARE · Cap: $3.48M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7695493% more annual revenue ($56.58B vs $735,200). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
ONCO
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for ONCO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -82.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ONCO
The strongest argument for ONCO centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : ONCO
The primary concerns for ONCO are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while ONCO is a value play — different risk/reward profiles.
ONCO carries more volatility with a beta of 2.72 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 25/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Onconetix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Onconetix Inc. is a pioneering biotechnology company dedicated to transforming cancer care through its innovative diagnostics and therapeutic solutions. Leveraging a proprietary technology platform, Onconetix focuses on early detection and personalized treatment strategies across various malignancies, addressing critical unmet needs in oncology. With a robust and diverse product pipeline, the company is strategically positioned to meet the growing demand for effective cancer therapies, significantly enhancing patient outcomes through its advanced research and development initiatives in this rapidly evolving field.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?